Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

Aclaris Therapeutics, Inc.46 enrolled

Overview

This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Rosacea

Interventions

Oxymetazoline HCL 1.0% CreamDRUG

Oxymetazoline HCl cream 1.0% once daily application

Energy-Based TherapyDEVICE

Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: -Documented clinical diagnosis of rosacea. Exclusion Criteria: * History of any of the following conditions: Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, cerebral or coronary insufficiency, thromboangiitis obliterans, scleroderma, Sjögren's syndrome, severe or unstable or uncontrolled cardiovascular disease, or any other current uncontrolled systemic disease * Diagnosis or presence of any of the following conditions: rosaceaconglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin, peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or chronic recurring facial acne * Current treatment with monoamine oxidase (MAO) inhibitors * Current treatment with niacin ≥ 500 mg/day * Greater than 3 inflammatory lesions on the face * History or current evidence of drug or alcohol abuse within 12 months prior to the screening visit.

Locations (4)

Center for Dermatology and Laser Surgery

Sacramento, California, United States

SkinCare Physicians

Chestnut Hill, Massachusetts, United States

Skin Laser and Surgery Specialists of NY/NJ

Hackensack, New Jersey, United States

Laser & Skin Surgery Center of New York Professional Corporation

New York, New York, United States

Outcomes

Primary Outcomes

Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE is defined as any untoward medical occurrence in a clinical study participant administered a medicinal product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not it is related to the medicinal (investigational) product. An SAE is any untoward medical occurrence or effect that, at any dose: Results in death, Is life-threatening, Requires or prolongs inpatient hospitalization, Results in persistent or significant disability/incapacity or Results in a congenital anomaly/birth defect.

Time frame: Baseline (Day 1) to Day 56

Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Clinical Erythema Assessment Scale at Any Time-point

The investigator will assess erythema in the treatment area using a 5-point scale. (Grade 0= Clear Skin with no signs of erythema, Grade 1=Almost clear of erythema, slight redness, Grade 2=Mild erythema, definite redness, Grade 3= Moderate erythema, marked redness, Grade 4=Severe erythema, fiery redness). The percentage of participants with at least a 1-point improvement (decrease) in the score compared to Baseline at any time-point will be reported.

Time frame: Baseline (Day 1) to Day 56

Percentage of Participants With at Least a 1-Grade Worsening From Baseline in the Clinician's Telangiectasia Assessment (CTA) at Any Time-point

The investigator will assess the overall severity of telangiectasia (spider veins) on the participant's facing using a 5-point scale where 0=Clear skin with no signs of telangiectasia to 4=Severe, with the presence of many visible telangiectasia. The percentage of participants with at least a 1-point worsening (increase) in the score compared to Baseline at any time-point will be reported.

Time frame: Baseline (Day 1) to Day 56

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.